151751-Najiba-Chargi

203 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 1. Patient, disease and outcome characteristics. Characteristic Total patients n = 153 (%) Patients with CDLT n = 37 (%) Without CDLT n = 116 (%) P value Gender Men 112 (73.2) 28 (75.7) 84 (72.4) 0.70* Women 41 (26.8) 9 (24.3) 32 (27.6) Age at diagnosis (years) Mean (SD) 59.9 (6.7) 61.1 (5.9) 59.5 (7.0) 0.20 $ Smoking Never Former 25 (16.3) 16 (10.5) 5 (13.5) 6 (16.2) 20 (17.2) 10 (8.6) 0.40 # Active 112 (73.2) 26 (70.3) 86 (74.1) Body mass index (kg/m 2 ) Mean (SD) 23.7 (4.1) 23.6 (3.8) 23.8 (4.2) 0.82 $ ACE-27 score 0 1 2 115 (75.2) 37 (24.2) 1 (0.7) 28 (75.7) 8 (21.6) 1 (2.7) 87 (75.0) 29 (25.0) 0 (0) 0.20 # Renal function eGFR >70 130 (85.0) 27 (79.4) 103 (93.6) 0.01* eGFR 60-70 14 (9.2) 7 (20.6) 7 (6.4) Tumor site Oropharynx,HPV+ 41 (26.8) 9 (24.3) 32 (27.6) 0.40 # Oropharynx, HPV- or unknown 51 (33.3) 12 (32.4) 39 (33.6) Hypopharynx 50 (32.7) 11 (29.7) 39 (33.6) Larynx 11 (7.2) 5 (13.5) 6 (5.2) T stage 1 15 (9.8) 4 (10.8) 11 (9.5) 0.23 # 2 46 (30.1) 10 (27.0) 36 (31.0) 3 48 (31.4) 12 (32.4) 36 (31.0) 4 44 (28.8) 11 (29.7) 33 (28.4) N stage 0 19 (12.4) 3 (8.1) 16 (13.8) 0.53 # 1 17 (11.1) 5 (13.5) 12 (10.3) 2a 9 (5.9) 4 (10.8) 5 (4.3) 2b 66 (43.1) 13 (35.1) 53 (45.7) 2c 35 (22.9) 10 (27.0) 25 (21.6) 3 7 (4.6) 2 (5.4) 5 (4.3) AJCC stage II 4 (2.6) 0 (0) 4 (3.4) 0.34 # 11